Published in Antimicrob Agents Chemother on April 01, 1981
Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol (1989) 1.71
Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob Agents Chemother (1982) 1.48
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet. Antimicrob Agents Chemother (1989) 1.13
Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro. Antimicrob Agents Chemother (1984) 1.08
Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice. Antimicrob Agents Chemother (1984) 1.07
Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses. Antimicrob Agents Chemother (1989) 0.92
Synergism among BIOLF-62, phosphonoformate, and other antiherpetic compounds. Antimicrob Agents Chemother (1982) 0.84
Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1. Antimicrob Agents Chemother (1989) 0.84
Alpha interferon and acyclovir treatment of herpes simplex virus in lymphoid cell cultures. Antimicrob Agents Chemother (1982) 0.84
Downregulation of cellular c-Jun N-terminal protein kinase and NF-κB activation by berberine may result in inhibition of herpes simplex virus replication. Antimicrob Agents Chemother (2014) 0.82
Synergistic effect of human leukocyte interferon and nonoxynol 9 against herpes simplex virus type 2. Antimicrob Agents Chemother (1985) 0.82
Prolonged herpes simplex virus latency in vitro after treatment of infected cells with acyclovir and human leukocyte interferon. Antimicrob Agents Chemother (1986) 0.82
Synergistic antiviral activity of acyclovir and interferon on human cytomegalovirus. Antimicrob Agents Chemother (1983) 0.80
Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with alpha-interferon against herpes simplex virus type 2 in mice. Antimicrob Agents Chemother (1984) 0.79
Comparative activities of selected combinations of acyclovir, vidarabine, arabinosyl hypoxanthine, interferon, and polyriboinosinic acid-polyribocytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculated mice. Antimicrob Agents Chemother (1984) 0.79
Potentiation by levamisole, methisoprinol, and adenine or adenosine of the inhibitory activity of human interferon against encephalomyocarditis virus. Antimicrob Agents Chemother (1986) 0.76
Synergistic activity of combinations of recombinant human alpha interferon and acyclovir, administered concomitantly and in sequence, against a lethal herpes simplex virus type 1 infection in mice. Antimicrob Agents Chemother (1985) 0.75
Biosynthetic human interferon treatment of herpetic keratitis. Trans Am Ophthalmol Soc (1983) 0.75
Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol (1968) 26.67
Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers. Lancet (1979) 2.90
Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother (1979) 2.75
Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine. Antimicrob Agents Chemother (1979) 2.10
Interferon and cytomegalovirus in vivo and in vitro. Proc Soc Exp Biol Med (1967) 1.85
Effect of interferon on experimental vaccinia and herpes-simplex virus infections in rabbits' eyes. Lancet (1960) 1.80
Effect of 9-(2-hydroxyethoxymethyl)guanine on herpesvirus-induced keratitis and iritis in rabbits. Antimicrob Agents Chemother (1978) 1.66
Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N Engl J Med (1979) 1.61
Clinical trials with exogenous interferon: summary of a meeting. J Infect Dis (1979) 1.36
Combined antiviral effects of interferon, adenine, arabinoside, hypoxanthine arabinoside, and adenine arabinoside-5'-monophosphate in human fibroblast cultures. Antimicrob Agents Chemother (1977) 1.27
Inhibition of Herpesvirus hominis replication by human interferon. Infect Immun (1975) 1.26
Differential sensitivity of herpes simplex virus types 1 and 2 to human interferon: antiviral effects of interferon plus 9-beta-D-arabinofuranosyladenine. J Infect Dis (1976) 1.21
Acylovir in oral and ganglionic herpes simplex virus infections. J Infect Dis (1979) 1.11
HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J (1990) 9.34
Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med (1997) 7.59
Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science (1991) 7.15
Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A (1992) 6.85
Ampicillin-resistant Haemophilus influenzae type B infection. JAMA (1974) 5.90
A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol (2000) 5.76
Association of antigenic type of Herpesvirus hominis with site of viral recovery. J Immunol (1967) 5.07
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Infection with herpes-simplex viruses 1 and 2. 3. N Engl J Med (1973) 3.89
Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA (1988) 3.89
Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A (1991) 3.82
Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther (1972) 3.78
An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature (1998) 3.69
A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med (1982) 3.66
The natural history of herpes simplex virus infection of mother and newborn. Pediatrics (1980) 3.65
Comparative study of diagnostic procedures for congenital cytomegalovirus infection. Pediatrics (1980) 3.53
Antigenic and biologic differences in herpesvirus hominis. Prog Med Virol (1968) 3.31
A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med (1989) 2.94
Herpesviridae. Definition, provisional nomenclature, and taxonomy. The Herpesvirus Study Group, the International Committee on Taxonomy of Viruses. Intervirology (1981) 2.92
Infection with herpes-simplex viruses 1 and 2. 1. N Engl J Med (1973) 2.87
Antibodies to Herpesvirus hominis types 1 and 2 in humans. I. Patients with genital herpetic infections. Am J Epidemiol (1970) 2.83
Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics (1980) 2.70
Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance. J Infect Dis (1982) 2.70
Typing of Herpesvirus hominis strains by a direct immunofluorescent technique. Proc Soc Exp Biol Med (1969) 2.64
Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother (1997) 2.64
Infection of the newborn with herpesvirus hominis. Adv Pediatr (1970) 2.61
Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus. Nature (1974) 2.55
Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol (1985) 2.54
Cytology and histopathology of cervical herpes simplex infection. Cancer (1966) 2.52
Different patterns of neurologic involvement with herpes simplex virus types 1 and 2: isolation of herpes simplex virus type 2 from the buffy coat of two adults with meningitis. J Infect Dis (1973) 2.52
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol (1971) 2.40
Genital infection with type 2 Herpes virus hominis. A commonly occurring venereal disease. Br J Vener Dis (1969) 2.40
Relation of pock size on chorioallantoic membrane to antigenic type of herpesvirus hominis. Proc Soc Exp Biol Med (1968) 2.34
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology (2001) 2.30
Antiviral activity of arabinosylthymine in herpesviral replication: mechanism of action in vivo and in vitro. Antimicrob Agents Chemother (1977) 2.28
Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis (1992) 2.25
Human monocyte-macrophage-mediated antibody-dependent cytotoxicity to herpes simplex virus-infected cells. J Immunol (1977) 2.21
Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods (1986) 2.16
Antibodies to Herpesvirus hominis types 1 and 2 in humans. II. Women with cervical cancer. Am J Epidemiol (1970) 2.15
A community surveillance system of infectious diseases in the greater Atlanta area. Am J Public Health Nations Health (1966) 2.11
Inhibitory effect of heparin on herpes simplex virus. J Bacteriol (1964) 2.11
Genital herpetic infection. Association with cervical dysplasia and carcinoma. Cancer (1969) 2.10
Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis (1999) 2.07
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest (2001) 2.05
Genital herpes simplex infection. Virologic and cytologic studies. Obstet Gynecol (1967) 1.95
Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol (1987) 1.89
Immune response to infection with Mycobacterium ulcerans. Infect Immun (2001) 1.82
Demonstration of exogenous genital reinfection with herpes simplex virus type 2 by restriction endonuclease fingerprinting of viral DNA. J Infect Dis (1979) 1.82
Quantitative analysis of genomic polymorphism of herpes simplex virus type 1 strains from six countries: studies of molecular evolution and molecular epidemiology of the virus. J Gen Virol (1994) 1.79
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells. Clin Exp Immunol (1977) 1.73
Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother (2001) 1.72
Multisite comparison of CD4 and CD8 T-lymphocyte counting by single- versus multiple-platform methodologies: evaluation of Beckman Coulter flow-count fluorospheres and the tetraONE system. The NIAID DAIDS New Technologies Evaluation Group. Clin Diagn Lab Immunol (2000) 1.71
A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. J Infect Dis (1990) 1.70
Leukocytosis and natural killer cell function parallel neurobehavioral fatigue induced by 64 hours of sleep deprivation. J Clin Invest (1994) 1.70
Antigens of Herpes simplex virus type 1 and 2-immunodiffusion and inhibition passive hemagglutination studies. Z Immunitatsforsch Exp Klin Immunol (1971) 1.67
Infection with herpes-simplex viruses 1 and 2. II. N Engl J Med (1973) 1.64
Type-specific surface antigens of cells infected with herpes simplex virus (1 and 2). Proc Soc Exp Biol Med (1971) 1.64
Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med (1996) 1.63
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (2000) 1.60
Marrow transplantation in chronic granulomatous disease: an update, with 6-year follow-up. J Pediatr (1988) 1.57
Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. Biochem Pharmacol (1993) 1.56
The structure of herpes simplex virus DNA and its application to molecular epidemiology. Ann N Y Acad Sci (1980) 1.52
The epidemiology of Type 2 (genital) herpes simplex virus infection. Obstet Gynecol Surv (1972) 1.52
Filamentous structures of type 2 Herpesvirus hominis infection of the chorioallantoic membrane. J Virol (1969) 1.50
Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother (2000) 1.49
Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob Agents Chemother (1982) 1.48
Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res (1986) 1.47
Infection in infants and children. Am J Dis Child (1977) 1.45
Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob Agents Chemother (1994) 1.43
Detection of antibodies to herpes simplex virus in the cerebrospinal fluid of patients with herpes simplex encephalitis. J Infect Dis (1987) 1.43
Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest (1995) 1.42
Early diagnosis of HIV infection in infants by detection of IgA HIV antibodies. Lancet (1990) 1.41
ELISA for the detection of herpes simplex virus antigens in the cerebrospinal fluid of patients with encephalitis. J Virol Methods (1983) 1.41
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother (1995) 1.39
Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis (2001) 1.38
Genital herpes simplex infection in the female. Am J Obstet Gynecol (1966) 1.38
Genital infection with Herpesvirus hominis types 1 and 2 in children. Pediatrics (1968) 1.38
Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst (1986) 1.38
Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother (1988) 1.36
Epidemiology of necrotizing enterocolitis: a case control study. J Pediatr (1980) 1.36
Cellular immunity in vaccinia infection of mice. Anti-thymocyte serum effects on primary and secondary responsiveness. J Exp Med (1968) 1.36
Stimulation of human lymphocytes by Herpes simplex virus antigens. Infect Immun (1975) 1.34
Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV). J Med Chem (1988) 1.33
1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. J Med Chem (1993) 1.31
Effect of antithymocyte serum on herpesvirus hominis (type 1) infection in adult mice. Proc Soc Exp Biol Med (1969) 1.31
Prospective studies of the association of genital herpes simplex infection and cervical anaplasia. Cancer Res (1973) 1.31
Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemiol (2001) 1.30
Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol (2000) 1.30
Intrauterine infection with herpes simplex virus. Resultant congenital malformations. JAMA (1973) 1.28
Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. Antimicrob Agents Chemother (1986) 1.28
Susceptibility of Haemophilus influenzae isolates from blood and cerebrospinal fluid to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother (1976) 1.27
Multiple drug effect analysis with confidence interval. Antiviral Res (1994) 1.26
Evidence for human infection with an HTLV III/LAV-like virus in Central Africa, 1959. Lancet (1986) 1.26
Ocular manifestation of herpes simplex in the newborn (neonatal ocular herpes). Int Ophthalmol Clin (1972) 1.25
3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. AIDS Res Hum Retroviruses (1990) 1.24